Merck shares are forming a bullish chart pattern, and a breakout could be on the horizon
While the health-care sector broadly continues to search for direction, drug stocks have been the clear leaders — and Merck stands out as one of the strongest performers in the group. Over the past few months, the stock has demonstrated a notable ability to leverage multi-week consolidation phases into clean breakouts and sustained advances. Since February, Merck has been quietly digesting its latest move, and it’s worth paying close attention to the structure taking shape. The developing base now resembles a potential inverse head-and-shoulders pattern — one of the more reliable bottoming formations in technical analysis. As with any pattern of this type, patience is key. Some additional consolidation beneath the noted resistance level would help further define the right shoulder and strengthen the overall setup before any breakout attempt. From a risk/reward standpoint, the trade is well-defined. A breakout above $124 would formally trigger the pattern, opening the door to an upside target near $135 — representing meaningful potential from current levels. Equally important is the timing. Merck does not report earnings until April 30, which gives this setup a valuable window to potentially trigger. Zooming way out to the quarterly chart — all the way back to the mid-1980s — the most recent advance over the last few months could still be in the very early stages of an eventual long-term comeback. Profiled here are the various instances over the past near-40 years where Merck endured a significant multi-month or even multi-year pullback, stabilized, and ultimately broke through a major downtrend line — marked in red. What followed those breakouts wasn’t just a modest bounce. We’re talking about powerful, sustained extensions that lasted for decades. This has played out four distinct times, most recently from 2009 through early 2024. If history is any guide — and on a chart this clean, it’s hard to ignore — then not only could Merck reclaim its former high just above $134, but it may also potentially extend well beyond that level over time. The near-term setup we outlined is compelling on its own, but the long-term context adds another dimension entirely. So how do we know if this rally has more room to run? We just covered the very short-term bullish pattern and the compelling long-term quarterly picture. Now let’s take a more intermediate view through the weekly log chart. From this perspective, the most important thing to watch going forward is how Merck behaves around its rising weekly moving averages. Over the last few years, when the stock has been at its best, that cluster of moving average lines has consistently acted as support. The lines have been trending higher — and when momentum has been behind the stock, price has respected them. When momentum faded, the stock rolled over, and those same lines flipped to resistance on the way down. A textbook example of that dynamic played out from early 2024 through early 2025. Thus, for this rally to prove itself and extend meaningfully further, we need to see those lines return to their support role. That doesn’t mean Merck has to hold above every single line at all times. But it does need to respect them the majority of the time. DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, or its parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL’S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
About the Author
Related
Discover more from InfoVera USA
Subscribe to get the latest posts sent to your email.
